Carol L Shields
Carol L Shields is an expert in Ophthalmology at Wills Eye Hospital (United States). As of October 2026, ScienceLeadR ranks Carol L Shields in the top 1% of experts worldwide for Eye Neoplasms, Uveal Diseases and Uveal Melanoma. Carol L Shields has authored 1,845 publications, the most recent in 2026, and is an investigator in 2 clinical trials. SLR score: 5,384 (community average: 125). How the SLR is computed.
LeadR Profile
Ophthalmology
Subspecialties: Oncology - Pediatrics - Surgery
Main Topics
Publications and Clinical Studies
Profile data updated on
Organizations
Career arc: 1988 - 2026
Number : 1845
Citations
Main journals
Best Journals
Breakdown by type
Click a legend label to hide or show it in the chart.
Latest Publications
5 most recent indexed articles
Source: Pubmed
| Title | Journal | Year | Citations |
|---|---|---|---|
| Choroidal melanoma in MSH2-associated Lynch syndrome. PMID 42907571 — ophthalmology, melanoma, uveal melanoma | Eye (Lond) | 2026 | 0 |
| Retinoblastoma management: achieving high standards of care. PMID 42839089 — eye, retinoblastoma, ophthalmology, melphalan, drug therapy, arteries, seeds, topotecan, carboplatin, chemotherapy | Eye (Lond) | 2026 | 0 |
| From Enucleation to Prevention: Evolution of Germline Retinoblastoma Management. PMID 42765613 — retinoblastoma, eye diseases, therapeutics | J Pediatr Ophthalmol Strabismus | 2026 | 1 |
| Uveal Hypopigmentation Revealing Waardenburg Syndrome. PMID 42720929 — hypopigmentation, eye diseases, waardenburg syndrome | JAMA Ophthalmol | 2026 | 0 |
| Global Patterns of Cross-Border Travel for Retinoblastoma Care. PMID 42623082 — travel, retinoblastoma, eye diseases | JAMA Ophthalmol | 2026 | 0 |
Clinical Studies 2
Synthesis
By phase:
By status:
By type:
By Monocentric/Multicentric:
Cohort/Consortium Investigators 4
LeadR Networks
Main global connection map